Gastrointestinal infectious disease complications following transplantation and their differentiation from immunosuppressant‐induced gastrointestinal toxicities
- 1 August 2001
- journal article
- review article
- Published by Wiley in Clinical Transplantation
- Vol. 15 (s4), 11-22
- https://doi.org/10.1111/j.1399-0012.2001.00011.x
Abstract
It is often very difficult to distinguish between infection‐related and immunosuppression‐related gastrointestinal (GI) complications after transplantation. The risk of infection itself is determined by the patient's net state of immunosuppression as well as the presence of anatomic or technical abnormalities and the patient's epidemiological exposures. Of the anatomic abnormalities, diverticulitis is a particular problem in transplant patients, with a high rate of perforation and abscess formation. The causes of infectious disease syndromes are very different immediately after, early after, and late after transplantation. Infection during the first month may result from a pre‐existing infection in the donor or recipient, or from the surgical wound, endotracheal tube, vascular access or drainage. During 1–6 months after transplantation, viruses attack and, with sustained immunosuppression, make opportunistic infections possible. Beyond 6 months after transplantation, the 80% of patients with good result from the transplant are at risk primarily for community‐acquired microbes, including such enteric pathogens as Salmonella. Of the remaining patients, 10% have chronic viral infections and the 10% who have poor allograft function are at greatest risk for opportunistic infection. This time line is helpful in determining whether a GI complication is likely to be related to infection rather than a specific effect of an immunosuppressant drug. Fever, inflammatory cells in the stool, abnormalities on endoscopy or computed tomography and leukocytosis can be useful in the diagnosis but are inconsistent markers for an infectious cause.Keywords
This publication has 10 references indexed in Scilit:
- SIROLIMUS IN ASSOCIATION WITH MYCOPHENOLATE MOFETIL INDUCTION FOR THE PREVENTION OF ACUTE GRAFT REJECTION IN RENAL ALLOGRAFT RECIPIENTS12Transplantation, 2000
- SAFETY AND EFFICACY OF TACROLIMUS IN COMBINATION WITH MYCOPHENOLATE MOFETIL (MMF) IN CADAVERIC RENAL TRANSPLANT RECIPIENTS1Transplantation, 2000
- Ogilvie's syndrome associated with acute cytomegaloviral infection after liver transplantationTransplant International, 2000
- Human Cytomegalovirus Reactivation in Bone-Marrow-Derived Granulocyte/Monocyte Progenitor Cells and Mature MonocytesIntervirology, 1999
- IMMUNOSUPPRESSIVE EFFECTS AND SAFETY OF A SIROLIMUS/CYCLOSPORINE COMBINATION REGIMEN FOR RENAL TRANSPLANTATION1Transplantation, 1998
- Infection in Organ-Transplant RecipientsNew England Journal of Medicine, 1998
- A BLINDED, LONG-TERM, RANDOMIZED MULTICENTER STUDY OF MYCOPHENOLATE MOFETIL IN CADAVERIC RENAL TRANSPLANTATIONTransplantation, 1998
- Peripheral T cell activation in long-term renal transplant patientsJournal of the American Society of Nephrology, 1996
- CYTOMEGALOVIRUS INFECTION AND GASTRIC EMPTYINGTransplantation, 1992
- CYTOMEGALOVIRUS INFECTION OF THE UPPER GASTROINTESTINAL TRACT BEFORE AND AFTER LIVER TRANSPLANTATIONTransplantation, 1988